Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-05
2011-04-05
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S388220, C536S023530
Reexamination Certificate
active
07919086
ABSTRACT:
An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6210670 (2001-04-01), Berg
patent: 6737056 (2004-05-01), Presta
patent: 7297775 (2007-11-01), Idusogie et al.
patent: 7361336 (2008-04-01), Bergstein
patent: 7427400 (2008-09-01), Bergstein
patent: 2004/0024320 (2004-02-01), Karasawa et al.
patent: 2004/0236080 (2004-11-01), Aburatani et al.
patent: 2005/0171339 (2005-08-01), Sugo et al.
patent: 2005/0233392 (2005-10-01), Filmus et al.
patent: 2006/0024298 (2006-02-01), Lazar et al.
patent: 2006/0040325 (2006-02-01), Wu et al.
patent: 2006/0167232 (2006-07-01), Aburatani et al.
patent: 2006/0188510 (2006-08-01), Aburatani et al.
patent: 2006/0287508 (2006-12-01), Sugo et al.
patent: 2007/0087005 (2007-04-01), Lazar et al.
patent: 2007/0172488 (2007-07-01), Aburtani et al.
patent: 2007/0269444 (2007-11-01), Kinoshita et al.
patent: 2008/0008710 (2008-01-01), Aburatani et al.
patent: 2008/0051563 (2008-02-01), Lazar et al.
patent: 2008/0124330 (2008-05-01), Nakano et al.
patent: 2008/0154025 (2008-06-01), Lazar et al.
patent: 2008/0161541 (2008-07-01), Lazar et al.
patent: 2008/0181890 (2008-07-01), Lazar et al.
patent: 2008/0267979 (2008-10-01), Lazar et al.
patent: 2010/0248359 (2010-09-01), Nakano et al.
patent: 1 176 195 (2002-01-01), None
patent: 1 331 266 (2003-07-01), None
patent: 1 411 118 (2004-04-01), None
patent: 1 462 799 (2004-09-01), None
patent: 1 464 702 (2004-10-01), None
patent: 1 498 491 (2005-01-01), None
patent: 1 548 442 (2005-06-01), None
patent: 1541680 (2005-06-01), None
patent: 1 561 686 (2005-08-01), None
patent: 1 671 645 (2006-06-01), None
patent: 1 674 111 (2006-06-01), None
patent: 1 800 693 (2007-06-01), None
patent: 1 816 140 (2007-08-01), None
patent: 2-42355 (1990-02-01), None
patent: 4-336051 (1992-11-01), None
patent: 11-118775 (1999-04-01), None
patent: 2001-108661 (2001-04-01), None
patent: 2002-48867 (2002-02-01), None
patent: 2003-149213 (2003-05-01), None
patent: 2004-053360 (2004-02-01), None
patent: 9322332 (1993-11-01), None
patent: 9823289 (1998-06-01), None
patent: WO 99/54342 (1999-10-01), None
patent: WO 00/61739 (2000-10-01), None
patent: WO 02/22739 (2002-03-01), None
patent: WO 02/31140 (2002-04-01), None
patent: WO 02/079255 (2002-10-01), None
patent: WO 03/000883 (2003-01-01), None
patent: WO 03/042686 (2003-05-01), None
patent: WO 03/057881 (2003-07-01), None
patent: WO 03/074679 (2003-09-01), None
patent: WO 03/085119 (2003-10-01), None
patent: WO 03/100429 (2003-12-01), None
patent: WO 2004/018667 (2004-03-01), None
patent: WO 2004/022597 (2004-03-01), None
patent: WO 2004/022739 (2004-03-01), None
patent: WO 2004/022754 (2004-03-01), None
patent: WO 2004/023145 (2004-03-01), None
patent: WO 2004/038420 (2004-05-01), None
patent: WO 2004/099249 (2004-11-01), None
patent: WO 2005/023301 (2005-03-01), None
patent: WO 2006/006693 (2006-01-01), None
patent: WO 2006/022407 (2006-03-01), None
patent: WO 2006/046751 (2006-05-01), None
patent: WO 2007/047291 (2007-04-01), None
Smith-Gill et al. (J. Immunol. 139:4135-4144 (1987)).
Kumar et al. (J. Biol. Chem. 275:35129-35136 (2000)).
Song et al. (Biochem Biophys Res Comm 268:390-394 (2000)).
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
Pascalis et al. (Journal of Immunology (2002) 169, 3076-3084).
Casset et al. ((2003) BBRC 307, 198-205).
Vajdos et al. ((2002) J. Mol. Biol. 320, 415-428).
Holm et al ((2007) Mol. Immunol. 44: 1075-1084).
Chen et al. (J. Mol. Bio. (1999) 293, 865-881).
Wu et al. J. Mol. Biol. ((1999) 294, 151-162).
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Dennis (Nature 442:739-741 (2006)).
Seaver (1994; Genetic Engineering vol. 14(14):pp. 10 and 21).
Dufner (Trends Biotechnol. 24(11):523-29 (2006)).
Bost et al. (Immunol. Invest. (1988) 17:577-586).
Bendayan (J. Histochem. Cytochem. (1995) 43:881-886).
Wichert et al. (Oncogene Jan. 29, 2004;23(4):945-55).
Steplewski et al. (Proc. Natl. Acad. Sci. USA, 1988 85: 4852-4856).
Capurro et al. “Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma”. Gastroenterology 125(1):89-97, Jul. 2003.
Capurro et al. “Overexpression of Glypican-3 in Human Hepatocellular Carcinomas Determined by immunohistochemistry using a monoclonal antibody”. Proceedings, American Association for Cancer Research, 93rdAnnual Meeting, Apr. 6-10, 2002, vol. 43, Abstract #1097, Mar. 2002.
Filmus. “Glypicans in Growth Control and Cancer”. Glycobiology, 11(3):19R-23R, 2001.
Gonzalez et al. “OCI-5/GPC3, A Glypican Encoded by a Gene That is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line-Specific Manner”. The Journal of Cell Biology, 141(6):1407-1414, 1998.
Huber. “Structure and Function of the Human Glypican 3 Gene”. Washington University, Division of Biology and Biomedical Sciences Program in Molecular Genetics, St. Louis, Missouri, Dec. 1998.
Lage et al. “Cloning and Characterization of Human cDNAs Encoding a Protein with High Homology to Rat Intestinal Development Protein OCI-5”. Gene 188:151-156, 1997.
Lage et al. “Expression of a Glypican-Related 62-kDa Antigen is Decreased in Hepatocellular Carcinoma in Correspondence to the Grade of Tumor Differentiation”. Virchows Arch, 438:567-573, 2001.
Midorikawa et al. “Glypican-3, Overexpressed in Hepatocellular Carcinoma, Modulates FGF2 and BMP-7 Signaling.” Int. J. Cancer 103:445-465, 2003.
Pilia et al. “Mutations in GPC3, A Glypican Gene, Cause the Simpson-Golabi-Behmel Overgrowth Syndrome”. Nature Genetics, 12:241-247, 1996.
Sung et al. “Glypican-3 is overexpressed in human hepatocellular carcinoma”. Cancer Science 94(3):259-262, Mar. 2003.
USPTO Restriction Requirement in U.S. Appl. No. 10/526,741, dated Mar. 27, 2006, 5 pages.
Davidson, Davidson & Kappel, LLC, Response to Restriction Requirement dated Mar. 27, 2006 in U.S. Appl. No. 10/526,741, filed Apr. 25, 2006, 6 pages.
USPTO Office Action in U.S. Appl. No. 10/526,741, dated Jun. 14, 2006, 40 pages.
Davidson, Davidson & Kappel, LLC, Amendment in Reply to Office Action dated Jun. 14, 2006 in U.S. Appl. No. 10/526,741, filed Dec. 12, 2006, 18 pages.
USPTO Final Office Action in U.S. Appl. No. 10/526,741, dated Mar. 9, 2007, 17 pages.
Davidson, Davidson & Kappel, LLC, Amendment in Reply to Office Action dated Mar. 9, 2007 in U.S. Appl. No. 10/526,741, filed Jul. 9, 2007, 9 pages.
USPTO Advisory Action in U.S. Appl. No. 10/526,741, dated Aug. 14, 2007, 3 pages.
Davidson, Davidson & Kappel, LLC, Amendment in Reply to Action dated Aug. 14, 2007 in U.S. Appl. No. 10/526,741, filed Sep. 6, 2007, 9 pages.
USPTO Office Action in U.S. Appl. No. 10/526,741, dated Nov. 21, 2007, 17 pages.
Davidson, Davidson & Kappel, LLC, Amendment in Reply to Action dated Nov. 21, 2007 in U.S. Appl. No. 10/526,741, filed Mar. 20, 2008, 10 pages.
USPTO Final Office Action in U.S. Appl. No. 10/526,741, dated Jul. 9, 2008, 11 pages.
Davidson, Davidson & Kappel, LLC, Amendment in Reply to Office Action dated Jul. 9, 2008 in U.S. Appl. No. 10/526,741, filed Jan. 5, 2009, 113 pages.
USPTO Advisory Action in U.S. Appl. No. 10/526,741, dated Jan. 21, 2009, 4 pages.
USPTO Office Action in U.S. Appl. No. 10/526,741, dated Sep. 1, 2009, 15 pages.
USPTO Final Office Action in U.S. A
Igawa Tomoyuki
Ishiguro Takahiro
Kawai Shigeto
Kinoshita Yasuko
Konishi Hiroko
Bristol Lynn
Chugai Seiyaku Kabushiki Kaisha
Fish & Richardson P.C.
LandOfFree
Anti-glypican 3 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-glypican 3 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-glypican 3 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679323